Quoin Pharmaceuticals (QNRX) Expected to Announce Quarterly Earnings on Monday

Quoin Pharmaceuticals (NASDAQ:QNRX) is projected to issue its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect the company to announce earnings of ($1.99) per share for the quarter. Parties can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, May 7, 2026 at 9:30 AM ET.

Quoin Pharmaceuticals (NASDAQ:QNRX) last issued its earnings results on Friday, March 27th. The company reported ($14.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($6.42) by ($8.38).

Quoin Pharmaceuticals Trading Up 1.2%

NASDAQ QNRX traded up $0.08 on Monday, hitting $6.29. 3,447 shares of the company were exchanged, compared to its average volume of 81,466. The company has a market cap of $11.31 million, a PE ratio of -0.18 and a beta of 1.61. Quoin Pharmaceuticals has a 12 month low of $5.20 and a 12 month high of $41.80. The stock has a fifty day moving average of $7.27 and a 200-day moving average of $10.73.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Quoin Pharmaceuticals in a research note on Wednesday, April 22nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Institutional Trading of Quoin Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in QNRX. ADAR1 Capital Management LLC purchased a new stake in Quoin Pharmaceuticals during the fourth quarter worth about $840,000. Boothbay Fund Management LLC bought a new position in shares of Quoin Pharmaceuticals in the fourth quarter valued at approximately $863,000. SummitTX Capital L.P. bought a new position in shares of Quoin Pharmaceuticals in the fourth quarter valued at approximately $935,000. Millennium Management LLC bought a new stake in Quoin Pharmaceuticals during the fourth quarter valued at approximately $1,080,000. Finally, Ikarian Capital LLC bought a new stake in Quoin Pharmaceuticals during the fourth quarter valued at approximately $3,052,000. Hedge funds and other institutional investors own 8.63% of the company’s stock.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc The company was founded in 2018 and is based in Ashburn, Virginia.